ArticleContraception and reproductive medicine2025
Prevalence and factors associated with the use of long-acting reversible and permanent contraceptive methods among women who desire no more children in Bangladesh.
Article in Contraception and reproductive medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLong-acting reversible and permanent contraceptive methods (LARC/PM) with high efficacy and continuity of use are highly effective pregnancy prevention methods. However, most sexually active women do not use it and end up with unintended pregnancies and unsafe abortions in Bangladesh. This study aims to assess the prevalence of LARC/PM use and its determinants among sexually active women who desire no more children in Bangladesh.
methodsThe study used Bangladesh Demographic and Health Survey (BDHS) 2017-18 data, which employed a two-stage cluster sampling design. This study extracted 6422 married women of reproductive age who desired no more children. Descriptive statistics were used to present the characteristics of the women. Chi-square and binary logistic regression were also used to identify the factors associated with LARC/PM use.
resultsA total of 20.2% of women use LARC/PM who desire no more children. Women aged 25-34 (aOR = 1.52, 95% CI: 1.10-2.09) and 35 years and above (aOR = 1.99, 95% CI: 1.41-2.81), women from Rangpur (aOR = 2.27, 95% CI = 1.57-3.28), Rajshahi (aOR = 2.15, 95% CI = 1.49-3.11), Khulna (aOR = 2.17, 95% CI = 1.48-3.17), Sylhet (aOR = 1.66, 95% CI = 1.07-2.58) and Dhaka (aOR = 1.97, 95% CI = 1.37-2.83) divisions, who were non-Muslims (aOR = 1.72, 95% CI = 1.40-2.11), having a desired number of children (2+) (aOR = 1.27, 95% CI = 1.08-1.49), whose contraceptive decision solely made by husband (aOR = 3.61, 95% CI = 2.73-1.77) or jointly (aOR = 1.59, 95% CI = 1.32-1.92) were more likely to use LARC/PM. On the other hand, women with primary education (aOR = 0.78, 95% CI = 0.65-0.92), secondary education (aOR = 0.59, 95% CI = 0.47-0.72) and higher education (aOR = 0.64, 95% CI = 0.43-0.95) belonging to richest wealth index (aOR = 0.73, 95% CI = 0.55-0.97), having at least two living children (aOR = 0.62, 95% CI = 0.44-0.85), partner with secondary education (aOR = 0.79 95% CI = 0.65-0.97) and women who were visited by family planning (FP) visitors (aOR = 0.34, 95% CI = 0.29-0.40) were less likely to use LARC/PM.
conclusionThe LARC/PM use rate among women in Bangladesh is low. It must be increased to meet the targets of the Sustainable Development Goals (SDGs). To increase LARC/PM use in Bangladesh, attention should be given to factors like women's age, education, partner's education, religion, wealth index, division, number of living children, and desired number of children.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.